SG11202108955QA - Antibody molecules that bind to nkp30 and uses thereof - Google Patents

Antibody molecules that bind to nkp30 and uses thereof

Info

Publication number
SG11202108955QA
SG11202108955QA SG11202108955QA SG11202108955QA SG11202108955QA SG 11202108955Q A SG11202108955Q A SG 11202108955QA SG 11202108955Q A SG11202108955Q A SG 11202108955QA SG 11202108955Q A SG11202108955Q A SG 11202108955QA SG 11202108955Q A SG11202108955Q A SG 11202108955QA
Authority
SG
Singapore
Prior art keywords
nkp30
bind
antibody molecules
antibody
molecules
Prior art date
Application number
SG11202108955QA
Other languages
English (en)
Inventor
Andreas Loew
Nidhi Malhotra
Madan Katragadda
Brian Vash
Stephanie Maiocco
Original Assignee
Marengo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marengo Therapeutics Inc filed Critical Marengo Therapeutics Inc
Publication of SG11202108955QA publication Critical patent/SG11202108955QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202108955QA 2019-02-21 2020-02-21 Antibody molecules that bind to nkp30 and uses thereof SG11202108955QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962808582P 2019-02-21 2019-02-21
PCT/US2020/019329 WO2020172605A1 (en) 2019-02-21 2020-02-21 Antibody molecules that bind to nkp30 and uses thereof

Publications (1)

Publication Number Publication Date
SG11202108955QA true SG11202108955QA (en) 2021-09-29

Family

ID=70005749

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108955QA SG11202108955QA (en) 2019-02-21 2020-02-21 Antibody molecules that bind to nkp30 and uses thereof

Country Status (9)

Country Link
US (1) US20210371523A1 (de)
EP (1) EP3927747A1 (de)
JP (1) JP2022521937A (de)
CN (1) CN114127111A (de)
AU (1) AU2020224681A1 (de)
CA (1) CA3130508A1 (de)
GB (1) GB2597851B (de)
SG (1) SG11202108955QA (de)
WO (1) WO2020172605A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230365709A1 (en) 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
CN114957469B (zh) * 2021-02-26 2024-02-20 盛禾(中国)生物制药有限公司 一种抗NKp30抗体及其应用
WO2022179580A1 (zh) * 2021-02-26 2022-09-01 盛禾(中国)生物制药有限公司 一种抗NKp30抗体及其应用
CN115124620B (zh) * 2021-03-29 2023-12-12 盛禾(中国)生物制药有限公司 一种能够激活nk细胞的抗体及其应用
EP4359437A2 (de) * 2021-06-22 2024-05-01 Merck Patent GmbH Vhh-basierte nkp30-bindemittel
EP4376958A1 (de) 2021-07-30 2024-06-05 Affimed GmbH Duplexkörper
WO2024056861A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for stimulating nk cells and use thereof

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5731116A (en) 1989-05-17 1998-03-24 Dai Nippon Printing Co., Ltd. Electrostatic information recording medium and electrostatic information recording and reproducing method
EP1892296A1 (de) 1988-09-02 2008-02-27 Dyax Corporation Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690935A3 (de) 1990-01-12 2008-07-30 Abgenix, Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2301198T3 (es) 1997-06-12 2008-06-16 Novartis International Pharmaceutical Ltd. Polipeptidos artificiales de anticuerpos.
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU775076B2 (en) 1998-12-10 2004-07-15 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
EP1163339A1 (de) 1999-04-01 2001-12-19 Innogenetics N.V. Eine polypeptidstruktur zur verwendung als gerüst
US6979546B2 (en) 1999-11-15 2005-12-27 Universita Di Genova Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
EP1474161A4 (de) 2002-01-16 2005-06-29 Zyomyx Inc Durch engineering hergestellte bindungsproteine
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
DE10261223A1 (de) * 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
US20080063717A1 (en) * 2002-12-23 2008-03-13 Innate Pharma, S.A.S. Pharmaceutical Compositions Having an Effect on the Proliferation of Nk Cells and a Method Using the Same
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2005028517A2 (en) 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
AU2004242614B2 (en) 2003-05-30 2011-09-22 Merus N.V. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20070231322A1 (en) 2004-04-30 2007-10-04 Innate Pharma, S.A. Compositions and Methods for Treating Proliferative Disorders Such as Nk-Type Ldgl
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
NZ552485A (en) 2004-08-05 2009-11-27 Genentech Inc Humanized anti-cmet antagonists
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
ES2629397T3 (es) 2004-09-24 2017-08-09 Amgen Inc. Moléculas de Fc modificadas
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
EP1934260B1 (de) 2005-10-14 2017-05-17 Innate Pharma Zusammensetzungen und methoden zur behandlung proliferierender krankheiten
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
CA2661042C (en) 2006-08-18 2012-12-11 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
WO2010031168A1 (en) 2008-09-17 2010-03-25 National Research Council Of Canada HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY
EP3521311A1 (de) 2008-04-11 2019-08-07 Chugai Seiyaku Kabushiki Kaisha Zur wiederholten bindung an zwei oder mehr antigenmoleküle fähiges, antigenbindendes molekül
WO2010112193A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
ES2708124T3 (es) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedimiento para preparar moléculas heteromultiméricas
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
CN103833855A (zh) 2009-06-26 2014-06-04 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
ES2688978T3 (es) 2009-11-23 2018-11-07 Amgen Inc. Anticuerpo monomérico Fc
US10584181B2 (en) 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
EP2542590B2 (de) 2010-03-05 2020-04-01 The Johns Hopkins University Zusammensetzungen und verfahren für gezielte immunmodulatorische antikörper und fusionsproteine
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011156328A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2808482C (en) 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
MX340556B (es) 2010-08-24 2016-07-14 Roche Glycart Ag Anticuerpos biespecificos activables.
CN101985476B (zh) * 2010-10-29 2012-11-21 中国科学技术大学 抗人NKp30单克隆抗体的制备、鉴定及应用
EP2635607B1 (de) 2010-11-05 2019-09-04 Zymeworks Inc. Design stabiler heterodimerer antikörper mit mutationen in der fc-domäne
EP2654792A4 (de) 2010-12-22 2016-05-11 Abbvie Inc Zur hälfte immunoglobulin-bindende proteine und verwendungen davon
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CA2812739A1 (en) 2011-03-25 2012-10-04 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
EP2728002B1 (de) 2011-06-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Heterodimerisiertes polypeptid
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
ES2857734T3 (es) 2011-08-23 2021-09-29 Roche Glycart Ag Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas
WO2013033626A2 (en) * 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
ES2767135T3 (es) 2011-10-19 2020-06-16 Novimmune Sa Métodos para purificar anticuerpos
JP6326371B2 (ja) 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
CA2859667C (en) 2011-12-20 2022-05-24 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
CN104185642A (zh) 2011-12-27 2014-12-03 财团法人生物技术开发中心 轻链桥连的双特异性抗体
MX2014009565A (es) 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
ES2728301T3 (es) 2012-03-13 2019-10-23 Novimmune Sa Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa
EP3421488A3 (de) 2012-03-14 2019-04-17 Regeneron Pharmaceuticals, Inc. Multispezifische antigenbindungsmoleküle und verwendungen davon
CN114163530A (zh) 2012-04-20 2022-03-11 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
CN104583239B (zh) 2012-05-10 2018-09-18 生物蛋白有限公司 多特异单克隆抗体
ES2843054T3 (es) 2012-05-10 2021-07-15 Zymeworks Inc Construcciones heteromultiméricas de cadenas pesadas de inmunoglobulina con mutaciones en el dominio Fc
RU2014149681A (ru) 2012-05-24 2016-07-20 Ф. Хоффманн-Ля Рош Аг Антитела с множественной специфичностью
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
CA2871386A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
CA2878587A1 (en) 2012-07-23 2014-01-30 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
WO2014022592A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
WO2014022540A1 (en) 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
EP2904093B1 (de) 2012-10-03 2019-04-10 Zymeworks Inc. Verfahren zur quantitativen bestimmung von schwer- und leichtkettigen polypeptidpaaren
CA2879768A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014100490A1 (en) 2012-12-19 2014-06-26 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
DK2940135T5 (da) 2012-12-27 2021-09-20 Chugai Pharmaceutical Co Ltd Heterodimeriseret polypeptid
KR20200134340A (ko) 2013-01-10 2020-12-01 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
WO2014124326A1 (en) 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP2970435B1 (de) 2013-03-15 2020-08-12 Eli Lilly and Company Verfahren zur herstellung von fabs und bispezifischen antikörpern
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
EP3878866A1 (de) 2013-04-29 2021-09-15 F. Hoffmann-La Roche AG Fc-rezeptor-bindende modifizierte asymmetrische antikörper und verfahren zur verwendung
WO2014186905A1 (en) 2013-05-24 2014-11-27 Zymeworks Inc. Modular protein drug conjugate therapeutic
WO2014190441A1 (en) 2013-05-31 2014-12-04 Zymeworks Inc. Heteromultimers with reduced or silenced effector function
EP3019522B1 (de) 2013-07-10 2017-12-13 Sutro Biopharma, Inc. Antikörper mit mehreren ortsspezifischen nichtnatürlichen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
WO2015027082A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
RU2758952C1 (ru) 2013-09-27 2021-11-03 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
JP6422956B2 (ja) 2013-10-11 2018-11-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性ドメイン交換共通可変軽鎖抗体
CN113248613A (zh) 2014-01-15 2021-08-13 豪夫迈·罗氏有限公司 具有修饰的FCRN结合性质的Fc区变体
EP3842455A1 (de) 2014-01-15 2021-06-30 F. Hoffmann-La Roche AG Fc-region-varianten mit verbesserter protein-a-bindung
KR20160107190A (ko) 2014-01-15 2016-09-13 에프. 호프만-라 로슈 아게 변형된 FcRn-결합 및 유지된 단백질 A-결합 성질을 갖는 Fc-영역 변이체
JP6731346B2 (ja) 2014-02-10 2020-07-29 メルク パテント ゲーエムベーハー 標的ＴＧＦβ阻害
DK3105252T3 (da) 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
WO2015127158A1 (en) 2014-02-21 2015-08-27 Regeneron Pharmaceuticals, Inc. Methods, compositions and kits for cell specific modulation of target antigens
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
DK3107938T3 (da) 2014-05-28 2022-07-11 Zymeworks Inc Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
AU2015279321B2 (en) 2014-06-27 2021-03-04 Innate Pharma, S.A. Multispecific antigen binding proteins
CN106573986A (zh) 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
CA2951599A1 (en) 2014-08-04 2016-02-11 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
WO2016071377A1 (en) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and protein a-binding properties
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
CN107207609B (zh) 2014-11-20 2022-07-19 豪夫迈·罗氏有限公司 共同轻链和使用方法
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
US10982008B2 (en) 2014-12-05 2021-04-20 Merck Patent Gmbh Domain-exchanged antibody
US9767555B2 (en) 2015-01-05 2017-09-19 Case Western Reserve University Disease characterization from fused pathology and radiology data
JP2018503399A (ja) 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
CN114249831A (zh) 2015-03-13 2022-03-29 诺夫免疫股份有限公司 纯化双特异性抗体的方法
EP3344660A4 (de) 2015-08-31 2019-07-03 National Research Council of Canada Tgf-beta-rezeptor-ektodomänenfusionsmoleküle und verwendungen davon
CA3016563A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof

Also Published As

Publication number Publication date
GB2597851A (en) 2022-02-09
US20210371523A1 (en) 2021-12-02
CA3130508A1 (en) 2020-08-27
EP3927747A1 (de) 2021-12-29
GB202112406D0 (en) 2021-10-13
AU2020224681A1 (en) 2021-09-16
GB2597851B (en) 2024-05-29
WO2020172605A1 (en) 2020-08-27
CN114127111A (zh) 2022-03-01
JP2022521937A (ja) 2022-04-13

Similar Documents

Publication Publication Date Title
GB2597851B (en) Antibody molecules that bind to NKP30 and uses thereof
IL271539A (en) CD73 antibody molecules and their use
IL267113A (en) Antibodies that specifically bind to human IL-15 and their uses
GB2599229B (en) Multifunctional molecules that bind to calreticulin and uses thereof
IL280004A (en) Antibody molecules that bind PD-L1 and CD137
IL287816A (en) Tigit antibody and its use
ZA201906813B (en) Antibody binding specifically to muc1 and use thereof
SG11202100172XA (en) Antibody molecules that bind cd137 and ox40
IL273572A (en) Antibodies to CD138 and their uses
SG10201912366YA (en) Anti-cd3 antibody and molecules comprising the antibody
GB2595980B (en) Anti-TCR antibody molecules and uses thereof
IL277588A (en) Monoclonal antibodies that bind to SSEA4 and their uses
IL266516B (en) An antibody that specifically binds to cd66c and its use
IL289034A (en) Human antibody molecules to cd138 and uses thereof
GB2607452B (en) Anti-TCR antibody molecules and uses thereof
GB2598218B (en) Anti-TCR antibody molecules and uses thereof
EP3527589A4 (de) Spezifisch an thioredoxin 1 bindender monoklonaler antikörper und verwendung dafür
HK1255409A1 (zh) 結合不動桿菌的抗體結合劑及其用途
GB202303286D0 (en) Antibody molecules that bind to nk30 and uses thereof
SG11202001813UA (en) Polypeptide and antibody bound to polypeptide
GB201818283D0 (en) Antibody molecules that bind PD-L1 and CD137
GB201811405D0 (en) Antibody molecules that bind PD-L1 and CD137
IL279570A (en) Antibody molecules to complement component 5 and their uses
GB201902594D0 (en) Antibody molecules that bind pd-l1 and cd137
ZA202001042B (en) Antibody specifically binding to pauf protein, and use thereof